酪氨酸激酶抑制剂治疗2年后未达主要分子学反应的慢性髓性白血病患者的长期结局
该分析报告了131例接受酪氨酸激酶抑制剂(TKI)治疗2年内未达主要分子学反应(MMR)的慢性髓性白血病(CML)患者的长期结局。2年内达主要细胞遗传学反应(MCyR,约相当于BCR::ABL1转录本国际标准[IS]<10%)者10年总生存(OS)为88%、CML相关总生存(CML-OS)为95%,且2年内达MCyR预测更好的OS(HR=0.43,p=.03)。诊断时年龄≥60岁者死亡主要与CML无关合并症有关(10年OS 55% vs 10年CML-OS 100%)。结论认为2年内达MCyR是CML的合理里程碑,即使未达MMR这些患者仍可有良好结局。
要点
- 2年内未达MMR的CML患者中,达MCyR者10年OS为88%、10年CML-OS为95%。
- 2年内达MCyR预测更好的OS(HR=0.43,p=.03)。
- 诊断时年龄≥60岁者10年OS为55% vs 10年CML-OS为100%,死亡主要与CML无关合并症有关。
核心结论
- 2年内达MCyR是CML的合理里程碑,即使未达MMR这些患者仍可有良好结局。
研究设计与样本
- 分析报告了131例接受TKI治疗2年内未达MMR的CML患者的长期结局。
主要发现
- 2年内达MCyR者10年OS为88%、10年CML-OS为95%。
- 2年内达MCyR预测更好的OS(HR=0.43,p=.03)。
- 诊断时年龄≥60岁者10年OS为55% vs 10年CML-OS为100%,死亡主要与CML无关合并症有关。
关键数值与推荐
- MCyR约相当于BCR::ABL1转录本水平国际标准(IS)<10%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Achieving major molecular response (MMR) with BCR::ABL1 tyrosine kinase inhibitors (TKIs) is associated with lower chances of progression to advanced phase disease and higher chances of treatment-free remission (TFR) in patients with chronic myeloid leukemia (CML). Failure to achieve this molecular milestone after 1 year has been highlighted as "suboptimal" or "warning" sign of treatment failure in CML guidelines and recommendations and implied to predict a poor long-term outcome. In this analysis, we report the long-term outcome of 131 patients who did not achieve MMR within the first 2 years of TKI therapy. Patients who achieved a major cytogenetic response (MCyR; roughly equivalent to BCR::ABL1 transcript levels on the International Scale [IS] <10%) had good long-term overall survival (OS) (10-year OS of 88%) and CML-related overall survival (CML-OS) (10-year CML-OS of 95%). The achievement of MCyR within the first 2 years of treatment predicted a better OS (HR = 0.43, p = .03). The value of MMR was even less pronounced among patients aged 60 years or older at diagnosis, in whom mortality was primarily due to comorbidities unrelated to CML (10-year OS of 55% vs. 10-year CML-OS of 100%). In conclusion, achievement of MCyR within 2 years is a reasonable milestone in CML, and these patients can still have good outcomes even when MMR is not achieved.
引用
- Bidikian A, Jabbour E, Issa GC, et al. Chronic myeloid leukemia without major molecular response after 2 years of treatment with tyrosine kinase inhibitor. Am J Hematol. 2023. PMID: 36606715. doi:10.1002/ajh.26836
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。